^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
LM103
i
Other names: LM103, Autologous tumor infiltrating lymphocytes, LM 103, LM-103
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Blue Horse Medical
Drug class:
Immunostimulant
Related drugs:
3ms
A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer (clinicaltrials.gov)
P2, N=45, Recruiting, Suzhou BlueHorse Therapeutics Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
LM103
4ms
A Multicenter, Randomized, Controlled, Open-label, Phase II Trial on Autologous Tumor Infiltrating Lymphocyte Injection (LM103 TILs) for the Treatment of Advanced Melanoma (ChiCTR2600118298)
P2, N=92, Beijing Cancer Hospital (Peking University Cancer Hospital); Beijing Cancer Hospital (Peking University Cancer Hospital)
New P2 trial
|
BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
BRAF mutation • NRAS mutation • BRAF V600 • BRAF positive
|
cisplatin • carboplatin • paclitaxel • temozolomide • dacarbazine • LM103
5ms
A Phase II Trial of LM103 in Advanced Melanoma (clinicaltrials.gov)
P2, N=92, Recruiting, Suzhou BlueHorse Therapeutics Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
BRAF mutation • NRAS mutation • BRAF V600
|
cisplatin • carboplatin • paclitaxel • temozolomide • dacarbazine • LM103
5ms
LM103 in Phase IIa Clinical Trial for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer (clinicaltrials.gov)
P2, N=45, Not yet recruiting, Suzhou BlueHorse Therapeutics Co., Ltd.
New P2 trial
|
LM103
7ms
A Phase II Trial of LM103 in Advanced Melanoma (clinicaltrials.gov)
P2, N=92, Not yet recruiting, Suzhou BlueHorse Therapeutics Co., Ltd.
New P2 trial
|
cisplatin • carboplatin • paclitaxel • temozolomide • dacarbazine • LM103
over1year
An Exploratory Clinical Study to Evaluate the Safety, Tolerability, Immune Response and Preliminary Efficacy of LM103 Injection in Combination With PD-1 in Patients With Advanced Solid Tumours (clinicaltrials.gov)
P1, N=10, Recruiting, Suzhou BlueHorse Therapeutics Co., Ltd.
New P1 trial • Combination therapy • Metastases
|
cyclophosphamide • LM103
3years
A Clinical Study on LM103 for the Treatment of Advanced Solid Tumors (clinicaltrials.gov)
P1, N=5, Recruiting, Suzhou BlueHorse Therapeutics Co., Ltd.
New P1 trial • Metastases
|
CD8 (cluster of differentiation 8) • MUC16 (Mucin 16, Cell Surface Associated) • CD4 (CD4 Molecule)
|
cyclophosphamide • LM103
Share via
